At 15.6% of CAGR, Drug-Eluting Balloon Market is Growing with $1,870.60 Mililion by 2027

Drug-eluting balloons are defined as the semi-compliant conventional angioplasty balloons that are covered with anti-proliferative drugs that are released in the walls of blood vessels during balloon inflation, majorly at nominal pressures. These balloons help to attenuate cellularity significantly and eliminates the need for repetitive vascularization.

According to a new market research study titled ‘‘Drug-Eluting Balloon Market to 2027 – Global Analysis and Forecasts by Product Type, End User and Geography. The global drug-eluting balloon market is expected to reach US$ 1,870.60 Mn in 2027 from US$ 516.65 Mn in 2018. The market is estimated to grow with a CAGR of 15.6% from 2019-2027.

The market is likely to grow due to significant increase in vascular disease incidences, growing product innovations and rising geriatric population. Whereas, the market is expected to have slow growth due to the high cost of procedures and products and stringent regulations for approval during the forecast period.

Get Sample PDF Copy at https://www.theinsightpartners.com/sample/TIPRE00003085?OpenPR+Simran

Drug-eluting balloons show various advantages over the drug-eluting stents. The balloons are developed with long-awaited new transcatheter technologies that have shown promising factors to reduce high restenosis rates in peripheral artery diseases.

Therefore, the drug-eluting balloons are enabled with various developments that are not available with the drug-eluting stents. For instance, drug delivery through the balloon does not require polymer or stent to deliver drugs, and can reduce the vascular inflammatory response. The responses are further directly related to very late thrombosis events, whereas drug-eluting stents require polymer-based drug coatings.

The other advantages of the DEB include faster delivery of drug kinetics to the vessel, and the intima is within 30–60 seconds of balloon inflation. Whereas, the drug delivery through DES is slow and have controlled the release of drug kinetics to block cell proliferation. Thus, the advantages of DEB over the DES are expected to increase the adoption of drug-eluting balloons in the coming years.

The global drug-eluting balloon market is segmented on the basis of product type, and end user. The market based on product type segment is classified as coronary drug eluting balloons, peripheral drug eluting balloons and other product types. Based on the end user the market is segmented as hospitals, cath labs & cardiac centers, and ambulatory surgical centers

Major players operating in the drug-eluting balloon market, Medtronic plc, Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits Limited, Terumo Corporation, Biotronik SE & Co. KG, and Innvolution Healthcare Pvt. Ltd. among others.

Buy Complete Report at https://www.theinsightpartners.com/buy/TIPRE00003085?OpenPR+Simran

Contact us –
Phone : +1-646-491-9876
Email Id : sales@theinsightpartners.com
Website: https://www.theinsightpartners.com

About Us - The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

This release was published on openPR.